Literature DB >> 26060214

Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing.

Balázs Csóka1, Zoltán H Németh1, Gábor Törő1, Marco Idzko1, Andreas Zech1, Balázs Koscsó1, Zoltán Spolarics1, Luca Antonioli1, Karolina Cseri1, Katalin Erdélyi1, Pál Pacher1, György Haskó2.   

Abstract

Extracellular ATP binds to and signals through P2X7 receptors (P2X7Rs) to modulate immune function in both inflammasome-dependent and -independent manners. In this study, P2X7(-/-) mice, the pharmacological agonists ATP-magnesium salt (Mg-ATP; 100 mg/kg, EC50 ≈ 1.32 mM) and benzoylbenzoyl-ATP (Bz-ATP; 10 mg/kg, EC50 ≈ 285 μM), and antagonist oxidized ATP (oxi-ATP; 40 mg/kg, IC50 ≈ 100 μM) were used to show that P2X7R activation is crucial for the control of mortality, bacterial dissemination, and inflammation in cecal ligation and puncture-induced polymicrobial sepsis in mice. Our results with P2X7(-/-) bone marrow chimeric mice, adoptive transfer of peritoneal macrophages, and myeloid-specific P2X7(-/-) mice indicate that P2X7R signaling on macrophages is essential for the protective effect of P2X7Rs. P2X7R signaling protects through enhancing bacterial killing by macrophages, which is independent of the inflammasome. By using the connexin (Cx) channel inhibitor Gap27 (0.1 mg/kg, IC50 ≈ 0.25 μM) and pannexin channel inhibitor probenecid (10 mg/kg, IC50 ≈ 11.7 μM), we showed that ATP release through Cx is important for inhibiting inflammation and bacterial burden. In summary, targeting P2X7Rs provides a new opportunity for harnessing an endogenous protective immune mechanism in the treatment of sepsis. © FASEB.

Entities:  

Keywords:  connexin; inflammasome; inflammation; pannexin; phagocytosis

Mesh:

Substances:

Year:  2015        PMID: 26060214      PMCID: PMC4550379          DOI: 10.1096/fj.15-272450

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  47 in total

Review 1.  Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation.

Authors:  M J L Bours; E L R Swennen; F Di Virgilio; B N Cronstein; P C Dagnelie
Journal:  Pharmacol Ther       Date:  2006-06-19       Impact factor: 12.310

2.  Intravenous injection of trauma-hemorrhagic shock mesenteric lymph causes lung injury that is dependent upon activation of the inducible nitric oxide synthase pathway.

Authors:  Maheswari Senthil; Anthony Watkins; Dimitrios Barlos; Da-Zhong Xu; Qi Lu; Billy Abungu; Frank Caputo; Rena Feinman; Edwin A Deitch
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

3.  Ecto-5'-nucleotidase (CD73) decreases mortality and organ injury in sepsis.

Authors:  György Haskó; Balázs Csóka; Balázs Koscsó; Rachna Chandra; Pál Pacher; Linda F Thompson; Edwin A Deitch; Zoltán Spolarics; László Virág; Pál Gergely; Rolando H Rolandelli; Zoltán H Németh
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

4.  A conditional knockout resource for the genome-wide study of mouse gene function.

Authors:  William C Skarnes; Barry Rosen; Anthony P West; Manousos Koutsourakis; Wendy Bushell; Vivek Iyer; Alejandro O Mujica; Mark Thomas; Jennifer Harrow; Tony Cox; David Jackson; Jessica Severin; Patrick Biggs; Jun Fu; Michael Nefedov; Pieter J de Jong; A Francis Stewart; Allan Bradley
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

Review 5.  Differentiating connexin hemichannels and pannexin channels in cellular ATP release.

Authors:  Alexander W Lohman; Brant E Isakson
Journal:  FEBS Lett       Date:  2014-02-15       Impact factor: 4.124

Review 6.  Pathophysiologic mechanisms in septic shock.

Authors:  Elizabeth G King; Gustavo J Bauzá; Juan R Mella; Daniel G Remick
Journal:  Lab Invest       Date:  2013-09-23       Impact factor: 5.662

7.  Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury.

Authors:  Almut Grenz; Hua Zhang; Marina Hermes; Tobias Eckle; Karin Klingel; Dan Yang Huang; Christa E Müller; Simon C Robson; Hartmut Osswald; Holger K Eltzschig
Journal:  FASEB J       Date:  2007-04-18       Impact factor: 5.191

Review 8.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

9.  Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria.

Authors:  Edward A Miao; Irina A Leaf; Piper M Treuting; Dat P Mao; Monica Dors; Anasuya Sarkar; Sarah E Warren; Mark D Wewers; Alan Aderem
Journal:  Nat Immunol       Date:  2010-11-07       Impact factor: 25.606

10.  The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques.

Authors:  Janine M van Gils; Merran C Derby; Luciana R Fernandes; Bhama Ramkhelawon; Tathagat D Ray; Katey J Rayner; Sajesh Parathath; Emilie Distel; Jessica L Feig; Jacqueline I Alvarez-Leite; Alistair J Rayner; Thomas O McDonald; Kevin D O'Brien; Lynda M Stuart; Edward A Fisher; Adam Lacy-Hulbert; Kathryn J Moore
Journal:  Nat Immunol       Date:  2012-01-08       Impact factor: 25.606

View more
  51 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  P2X4 receptors, immunity, and sepsis.

Authors:  Luca Antonioli; Corrado Blandizzi; Matteo Fornai; Pál Pacher; H Thomas Lee; György Haskó
Journal:  Curr Opin Pharmacol       Date:  2019-03-25       Impact factor: 5.547

Review 3.  Purinergic receptors as potential therapeutic targets in Alzheimer's disease.

Authors:  Lucas T Woods; Deepa Ajit; Jean M Camden; Laurie Erb; Gary A Weisman
Journal:  Neuropharmacology       Date:  2015-10-28       Impact factor: 5.250

Review 4.  Purinergic Signaling and the Immune Response in Sepsis: A Review.

Authors:  Carola Ledderose; Yi Bao; Yutaka Kondo; Mahtab Fakhari; Christian Slubowski; Jingping Zhang; Wolfgang G Junger
Journal:  Clin Ther       Date:  2016-05-05       Impact factor: 3.393

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

6.  POM-1 inhibits P2 receptors and exhibits anti-inflammatory effects in macrophages.

Authors:  Gabriela Pimenta-Dos-Reis; Eduardo José Lopes Torres; Paula Gabriela Quintana; Lincon Onorio Vidal; Bárbara Andréa Fortes Dos Santos; Chuan-Sheng Lin; Norton Heise; Pedro Muanis Persechini; Julieta Schachter
Journal:  Purinergic Signal       Date:  2017-10-11       Impact factor: 3.765

7.  Macrophage P2X4 receptors augment bacterial killing and protect against sepsis.

Authors:  Balázs Csóka; Zoltán H Németh; Ildikó Szabó; Daryl L Davies; Zoltán V Varga; János Pálóczi; Simonetta Falzoni; Francesco Di Virgilio; Rieko Muramatsu; Toshihide Yamashita; Pál Pacher; György Haskó
Journal:  JCI Insight       Date:  2018-06-07

Review 8.  The role of connexin and pannexin containing channels in the innate and acquired immune response.

Authors:  Silvana Valdebenito; Andrea Barreto; Eliseo A Eugenin
Journal:  Biochim Biophys Acta Biomembr       Date:  2017-05-27       Impact factor: 3.747

9.  CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.

Authors:  Luiz Eduardo Baggio Savio; Paola de Andrade Mello; Vanessa R Figliuolo; Thiago F de Avelar Almeida; Patrícia T Santana; Suellen D S Oliveira; Claudia L M Silva; Linda Feldbrügge; Eva Csizmadia; Richard D Minshall; Maria Serena Longhi; Yan Wu; Simon C Robson; Robson Coutinho-Silva
Journal:  J Hepatol       Date:  2017-05-26       Impact factor: 25.083

10.  Deletion of P2X7 attenuates hyperoxia-induced acute lung injury via inflammasome suppression.

Authors:  Lakshmi Galam; Ashna Rajan; Athena Failla; Ramani Soundararajan; Richard F Lockey; Narasaiah Kolliputi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.